Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05887609 · ClinicalTrials.gov registry record · Phase 2
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
A Phase 2 study of Fallopian Tube Cancer and Peritoneal Cancer, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 5
- Study locations
NCT05887609: Recruiting Phase 2 study of Fallopian Tube Cancer and Peritoneal Cancer, sponsored by University of Colorado, Denver.
NCT05887609 is a Phase 2 study of Fallopian Tube Cancer and Peritoneal Cancer that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 53 participants, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (79% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05887609, a Phase 2 study of Fallopian Tube Cancer and Peritoneal Cancer, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 5
- Study locations
Study Summary
The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.
Primary Outcome
PFS will be defined as the time from first dose of MIRV and Olaparib until investigator-assessed radiologic PD or death, whichever occurs first
Conditions Studied
Interventions
- DRUG Olaparib
- DRUG Mirvetuximab Soravtansine-gynx
Study Locations (5)
Pennsylvania
- University of Pennsylvania Health System, Perelman Center for Advanced Medicine - Philadelphia
- UPMC Magee-Women's Hospital - Pittsburgh
Colorado
- University of Colorado Hospital - Aurora
Illinois
- Northwestern Memorial Hospital - Chicago
Wisconsin
- University of Wisconsin - Carbone Cancer Center - University Hospital - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
What NCT05887609 shows while recruiting
NCT05887609 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (79% lower).
The record links to 3 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 2 interventions - of which Olaparib is the first listed.
NCT05887609 lists 5 locations in 4 states (Pennsylvania, Colorado, Illinois).
Frequently Asked Questions
What is clinical trial NCT05887609 about?
NCT05887609 is a clinical study titled "An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib". The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.
What is the current status of trial NCT05887609?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2023-10-03. Estimated completion is 2028-10.
What conditions does trial NCT05887609 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Peritoneal Cancer, Ovary Cancer.
What interventions are being tested in trial NCT05887609?
The interventions under investigation include: Olaparib (DRUG), Mirvetuximab Soravtansine-gynx (DRUG).
Who is sponsoring clinical trial NCT05887609?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05887609 being conducted?
This trial has 5 study locations across Colorado, Illinois, Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05887609's enrollment target sits among peer trials
53 47th of 85 higher than 39 of 85 other Fallopian Tube Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fallopian Tube Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
RECRUITING · Phase 2
-
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RECRUITING · Phase 2
-
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RECRUITING · Phase 2
-
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI